The global patient-derived xenograft model market size was valued at USD 227.8 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 12.8% from 2022 to 2030. The factors driving the market for the patient-derived xenograft(PDX) model include the increase in cancer cases, the pharmaceutical industry’s rising R&D activities, and ongoing public & private sector support for cancer research. During the COVID-19 pandemic, cancer research was halted as the majority of studies were focused on developing drugs for COVID-19. However, post-pandemic, the majority of the focus of researchers has been on developing innovative therapies for cancer. This is expected to support the growth of the industry.
The pandemic reduced cancer diagnosis and screening, which impacted the market. For instance, according to a study published in December 2021, titled “Cancer Case Trends Following the Incidence of the COVID-19 Pandemic: A Community-Based Observational Study with Extended Follow-up”, a significant drop in cancer diagnoses was reported in the early stages of the COVID-19 pandemic. PDX models of many cancer types have recently been widely developed due to the limitations of animal models & cell line models in preclinical research. PDX models are better depictions of the tumor heterogeneity and tumor microenvironment with retention of the cellular complexity, stromal architecture, and cytogenetics.
PDX models are increasingly recognized as an effective tool for identifying the characteristics of cancer, creating novel treatments, and predicting therapeutic success. In recent years, there has been a rise in attempts to develop PDX models of ovarian tumors to understand carcinogenesis. The engraftment rate varies depending on the various malignancies and tumor types. Cervical cancer PDX models had an engraftment success rate that ranged from 66.7% to 71.4%, whereas endometrial cancer PDX models had an engraftment success rate that ranged from 60% to 86%. Engraftment success in PDX models for ovarian cancer ranged from 45.5% to 100%. Thus, the rising number of cervical cases & ovarian cancer drives the growth of the industry.
The governments of various nations are taking steps to increase awareness of cancer and ways to diagnose it so that it can be detected early. For instance, the Tamil Nadu government is involved in developing the policy to identify 66.0% of cancer patients in the first and second stages by 2030 so that appropriate treatment can be made available, according to the state’s health minister in February 2022. Consequently, it is anticipated that such a policy would fuel industry expansion. Animal xenograft models are used to evaluate the effectiveness of pharmaceuticals. They are primarily employed for cancer, diabetes, and infectious disease tests and medication research. The in vivo activity of cancer has regularly been assessed using the mouse model.
The breast cancer segment dominated the global industry in 2021 and accounted for the largest share of more than 32.50%of the total revenue. The most common cause of mortality for women globally is breast cancer, despite significant advancements in diagnosis and treatment techniques over the years. It is difficult to completely eradicate tumors with current therapies as they are composed of populations that are quite heterogeneous, including those of breast cancer. It is also challenging to precisely predict drug efficacy using currently used cancer models, such as cell lines produced in vitro and in vivo, due to the inter-tumor heterogeneity of breast cancer.
Thus, PDX models have been developed to more accurately represent the heterogeneity of human cancers of origin. These models are anticipated to enhance treatment approaches for treating breast cancer. The other cancer segment includes colorectal, ovarian, renal cell carcinoma, sarcoma, and a few others. The other segment is anticipated to register the fastest growth rate during the forecast period. A rise in the number of cases of the above-mentioned cancers drives the growth of the industry. For instance, according to a study by National Cancer Institute (NIH), colorectal cancer is rising rapidly among young adults. It is the primary cause of cancer death in the U.S. under the age of 50 years, and the rate of new diagnosis is continually rising in this age range.
The mice model type segment accounted for the maximum revenue share of 70.4% in 2021. The mouse is the foremost mammalian model for examining human illness and health. The mouse is a small, pragmatic option that replicates well. After studying mice for more than a century, researchers have accumulated a plethora of information about their physiology, anatomy, and genes. The mice have a rapid reproductive cycle, and a long lifetime (one mouse year is equivalent to around 30 human years), which keeps the price, time, and space needed for the study manageable. The abovementioned factors & advantages drive the growth of the segment. The rats model segment is anticipated to register the fastest growth rate during the forecast period.
Human cancer xenografts in rats have been a crucial technique in introducing new drugs from the lab to the clinics & can offer predictive data on the success of candidate drugs in clinical trials.PDX enables better modeling of the molecular characteristics, heterogeneity, and pathology of the original tumor and for predicting therapy sensitivity by directly transplanting tumor tissue into rats following a biopsy from the patient. In addition, it allows the development of tumor forms for which cell line synthesis has not been feasible. Despite the numerous advantages of this method for preclinical research, PDX rat models are restricted by low engraftment rates and delayed tumor development kinetics. However, OncoRat's impressive tumors take rates and growth dynamics for NSCLC PDXs aid in overcoming these drawbacks.
Based on end-user, the industry is segmented into pharmaceutical & biopharmaceutical companies, CROs & CDMOs, and academic and research institutes. The CROs & CDMOs segment accounted for the largest revenue share of 43.5% and is also anticipated to register the fastest CAGR during the forecast period. An increase in activities, such as mergers & acquisitions, expansion of services, and pharmaceutical & biopharmaceutical companies outsourcing their research activities will contribute to the growth of this segment. For instance, Envigo acquired the assets of Horizon Discovery Unit Plc’s Research Models Business Unit in 2019. The pharmaceutical & biopharmaceuticals companies segment also held a significant revenue share in 2021.
A growing number of research projects by these companies in the areas of personalized medicine and cancer is the key factor contributing to the segment growth. PDX clinical trials are essential to assess anti-cancer treatments before a human clinical trial. In consideration of these characteristics of cancer models, research institutions and pharmaceutical firms have created PDX collections. The PDX library has been made accessible by the Novartis Institute of Biomedical Research. More than a thousand Avatar mice with different malignant tissues have been produced by Novartis for this experiment. Preclinical investigations of drug evaluation and co-clinical trials are also where PDXs are most frequently used. As a result, major pharmaceutical companies are striving to establish a PDX archive for use in preclinical cancer treatment development.
North America accounted for the largest share of more than 48.50% of the global revenue in 2021. An increase in cancer cases, rising governmental & private sector investments, and the presence of important players in the area are all the key contributing factors. For instance, Precision Oncology Research received a USD 350,000 grant from the Breast Cancer Society of Canada in May 2022. By concentrating on improvements in screening, detection, precision oncology, and patient-reported outcomes, the breast cancer research project chosen for funding will enhance the care of Canadian women with breast cancer.
According to research issued by the WHO, in February 2021, it is anticipated that in 2022, almost 28,000 Canadians would receive a breast cancer diagnosis. Therefore, it is projected that such occurrences would fuel industry expansion in this region. Asia Pacific is projected to be the fastest-growing region over the forecast period due to China’s high research spending and the well-developed CRO sector, Japan’s expansion in biomedical & medical research, India’s rising pharmaceutical R&D spending, and Singapore’s expanding translational and biomedical research. The rising cancer burden in the region further supports the growth of the industry.
For instance, according to the journal sage 169.1 per 100,000 cancer incidence rate in 2020, which was 49.3% of the global cancer incidence rate. Lung (13.8%), breast (10.8%), and colorectal (10.6%) cancers were the most prevalent types of cancer in the region. Lung (19.2%), liver (10.5%), and stomach (9.9%) cancers are the most causative factors of cancer death, with a mortality rate of 101.6 per 100,000 (58.3% of all cancer deaths worldwide).
Key players are adopting a variety of strategic activities, such as the signing of a new partnership agreement, collaborations, mergers & acquisitions, and geographic expansions, to strengthen their services and gain a competitive advantage. For instance, the strategic license deal between Charles River Laboratories, Inc. and GemPharmatech for the exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mice lines in North America was announced in July 2022. Charles River would create foundation colonies and start in 2023, the models would be sold commercially. Some of the prominent players in the global patient-derived xenograft model market include:
Charles River Laboratories
The Jackson Laboratory
Patient-derived Xenograft Model Market Report Scope
Market Size value in 2022
USD 251.5 million
Revenue forecast in 2030
USD 661.4 million
CAGR 12.8% from 2022 to 2030
Base year for estimation
2018 - 2020
2022 - 2030
Revenue in USD million and CAGR from 2022 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Tumor type, model type, end-user, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; Japan; China; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE
Revenue forecast, company share, competitive landscape, growth factors, and trends
Key companies profiled
Charles River Laboratories; The Jackson Laboratory; Crown Bioscience; Altogen Labs; Envigo; WuXi AppTec; Oncodesign; Hera Biolabs; XenTech; Abnova Corp.
15% free customization scope (equivalent to 5 analysts working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global patient-derived xenograft model market report on the basis of tumor type, model type, end-user, and region:
Tumor Type Outlook (Revenue, USD Million, 2018 - 2030)
Model Type Outlook (Revenue, USD Million, 2018 - 2030)
End-user Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical And Biopharmaceutical Companies
Academic & Research Institutes
CROs & CDMOs
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global patient-derived xenograft model market size was estimated at USD 227.8 million in 2021 and is expected to reach USD 251.5 million in 2022.
b. The global patient-derived xenograft model market is expected to grow at a compound annual growth rate of 12.8% from 2022 to 2030 to reach USD 661.4 million by 2030.
b. By tumor type, the breast cancer segment dominated the patient-derived xenograft model market with a share of 32.9% in 2021 as the majority of the PDX model were developed for breast cancer.
b. Some key players operating in the patient-derived xenograft model market include Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs.
b. The global patient-derived xenograft model market is projected to expand rapidly due to the rising number of cancer cases across the globe, increasing R&D investment for cancer research, and an increasing number of Contract Research Organizations (CROs).
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."